Exicure Announces Appointment of James Sulat to Board of Directors
January 05 2021 - 7:00AM
Business Wire
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced the appointment of James Sulat to its
Board of Directors.
James “Jim” Sulat joins Exicure after decades of experience
advising and leading biopharmaceutical companies, including serving
in the roles of President, Chief Executive Officer and Chief
Financial Officer at various companies. Mr. Sulat currently serves
on the boards of directors of Valneva SE and Arch Therapeutics and
previously served on the boards of directors of other companies
including AMAG Pharmaceuticals, Momenta Pharmaceuticals and Tolero
Pharmaceuticals. Mr. Sulat served in several roles at Memory
Pharmaceuticals from 2005 to 2009, a biopharmaceutical company
focused on developing innovative drugs for the treatment of
debilitating CNS disorders, which was acquired by Roche. Mr. Sulat
holds a Bachelor of Science in Administrative Sciences from Yale
University and a Master of Business Administration and a Master of
Science in Health Services Administration from Stanford
University.
“We are pleased to welcome Jim to our board. His extensive
biopharmaceutical experience in business development, finance and
building companies will be an asset to our Board and beneficial to
Exicure’s future growth," said Timothy P. Walbert, Chairman of
Exicure’s Board of Directors.
Exicure also announced today that Jay Venkatesan has stepped
down from the Board of Directors, effective December 29, 2020.
“We would like to thank Jay for his tremendous support and
guidance during the early formation and growth of Exicure,” said
Dr. Giljohann, Exicure’s Chief Executive Officer.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for immuno-oncology, inflammatory diseases
and genetic disorders based on our proprietary Spherical Nucleic
Acid, or SNA technology. We believe Exicure's proprietary SNA
architecture has distinct chemical and biological properties that
may provide advantages over other nucleic acid therapeutics and may
have therapeutic potential to target diseases not typically
addressed with other nucleic acid therapeutics. Exicure's lead
program is in a Phase1b/2 trial in patients with advanced solid
tumors. Exicure is based outside of Chicago, IL.
www.exicuretx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210105005247/en/
MacDougall Karen Sharma 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024